Browsing BioMed Central høstingsarkiv by Author "Vik-Mo, Einar O"

Now showing items 1-3 of 3

  • Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment 
    Skaga, Erlend; Kulesskiy, Evgeny; Brynjulvsen, Marit; Sandberg, Cecilie J; Potdar, Swapnil; Langmoen, Iver A; Laakso, Aki; Gaál-Paavola, Emília; Perola, Markus; Wennerberg, Krister; Vik-Mo, Einar O (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    Background Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics-driven oncology for ...
  • Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma 
    Skaga, Erlend; Kulesskiy, Evgeny; Fayzullin, Artem; Sandberg, Cecilie J; Potdar, Swapnil; Kyttälä, Aija; Langmoen, Iver A; Laakso, Aki; Gaál-Paavola, Emília; Perola, Markus; Wennerberg, Krister; Vik-Mo, Einar O (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    Background A major barrier to effective treatment of glioblastoma (GBM) is the large intertumoral heterogeneity at the genetic and cellular level. In early phase clinical trials, patient heterogeneity in ...
  • Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells 
    Mughal, Awais A; Grieg, Zanina; Skjellegrind, Håvard; Fayzullin, Artem; Lamkhannat, Mustapha; Joel, Mrinal; Ahmed, M. S; Murrell, Wayne; Vik-Mo, Einar O; Langmoen, Iver A; Stangeland, Biljana (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2015)
    Background Glioblastoma (GBM) is the most common primary brain malignancy and confers a dismal prognosis. GBMs harbor glioblastoma-initiating cells (GICs) that drive tumorigenesis and contribute to therapeutic ...